Comparative Pharmacology
Head-to-head clinical analysis: MARPLAN versus PARNATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MARPLAN versus PARNATE.
MARPLAN vs PARNATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Irreversible, non-selective monoamine oxidase inhibitor (MAOI) that increases synaptic concentrations of monoamine neurotransmitters (serotonin, norepinephrine, dopamine, tyramine) by inhibiting their oxidative deamination.
Irreversible non-selective monoamine oxidase inhibitor (MAOI-A and MAOI-B); increases synaptic concentrations of serotonin, norepinephrine, and dopamine by inhibiting their oxidative deamination.
10 mg orally 3 times daily initially, increased to 20 mg 3 times daily; maintenance 10-20 mg 3 times daily.
10 mg orally twice daily; increase by 10 mg/day at 1-week intervals up to 60 mg/day; usual therapeutic range 30-60 mg/day in divided doses.
None Documented
None Documented
Terminal elimination half-life ranges from 2.5 to 4 hours, but due to irreversible inhibition of monoamine oxidase (MAO), the pharmacodynamic effect persists for up to 2-3 weeks after discontinuation until new enzyme synthesis occurs.
Terminal half-life approximately 2.5 hours; clinically, MAO inhibition persists for 2-3 weeks post discontinuation due to irreversible enzyme binding.
Primarily renal excretion of metabolites, with less than 1% excreted unchanged; approximately 60-70% of a dose is recovered in urine within 24 hours, mainly as isocarboxazide metabolites; minor biliary/fecal elimination accounts for the remainder.
Renal (90% as metabolites, <1% unchanged); fecal (minor).
Category C
Category C
MAOI Antidepressant
MAOI Antidepressant